6 Results for "

Adverse Drug Reactions

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Adverse Drug Reactions" in MCE Product Catalog:

Cat. No.: HY-109547
CAS No.: 119623-66-4
Purity:  99.95%
Synonyms: Diclofenac hydroxyethylpyrrolidine
Target:  

COX

Research Areas:  

Inflammation/Immunology Cancer

Flector Patch (Diclofenac epolamine) is a non-steroidal anti-inflammatory drug (NSAID) . Flector Patch is used for relieving arthritis Pain, acute Pain, osteoarthritis, and actinic Keratosis. Flector Patch has good skin absorption characteristics without local adverse reactions and allergies .
loading...
    loading...
Cat. No.: HY-107962
CAS No.: 18656-21-8
Synonyms: Renovue 65
Research Areas:  

Others

Iodamide meglumine (Renovue 65) is a type of trityl ion contrast agent. Iodamide meglumine can block X-rays and is used in examinations such as cholangiography and cholecystography to display the gallbladder and bile ducts. Iodamide meglumine has the property of renal tubular active secretion. Iodamide meglumine can be used for intravenous urography .
loading...
    loading...
Cat. No.: HY-W008613A
CAS No.: 17086-03-2
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease Cancer

Amitriptyline pamoate is a common oral anticholinergic. Amitriptyline pamoate has anticholinergic properties. Amitriptyline pamoate can be used to quantify anticholinergic adverse reactions in patients taking amitriptyline and placebo .
loading...
    loading...
Cat. No.: HY-L225
259 compounds

Drug development is both expensive and time-consuming, with approximately one-third of drug discontinuations caused by severe adverse drug reactions (ADRs). Among these, drug-induced cardiotoxicity (DICT) is one of the primary reasons for late-stage clinical drug failures and market withdrawals. To date, cardiotoxicity has been observed in multiple drug classes, such as anticancer drugs, antipsychotics, antidepressants, antibiotics, and neurodegenerative disease medications. To reduce cardiac ADRs, it is crucial to determine the clinical relevance of DICT to treatment, elucidate the underlying molecular mechanisms, identify reliable biomarkers, and develop new diagnostic and therapeutic approaches.

MCE offers 259 cardiotoxicity compounds, including some FDA-approved drugs as well as inhibitors/blockers of the hERG potassium channel.

Cat. No.: HY-109547R
CAS No.: 119623-66-4
Synonyms: Diclofenac hydroxyethylpyrrolidine (Standard)
Target:  

Reference Standards COX

Research Areas:  

Inflammation/Immunology Cancer

Diclofenac epolamine (Standard) is the analytical standard of Diclofenac epolamine (HY-109547). This product is intended for research and analytical applications. Flector Patch (Diclofenac epolamine) is a non-steroidal anti-inflammatory drug (NSAID) . Flector Patch is used for relieving arthritis Pain, acute Pain, osteoarthritis, and actinic Keratosis. Flector Patch has good sKin absorption characteristics without local adverse reactions and allergies .
loading...
    loading...
Cat. No.: HY-L140
232 compounds

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.

Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.

MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.